Dividends reached my AJ Bell accounts this morning .... ;0) |
*GSK NEARS $1BN DEAL FOR BIOTECH IDRX DEVELOPING DRUG FOR RARE TUMOUR- FT |
However, the available evidence was insufficient to establish a causal relationship, the FDA said.
(The risks flagged in the prescribing information of GSK's Arexvy and Pfizer's Abrysvo were not the regulator's strictest "boxed" warnings.) |
 Not going to help sentiment sadly..
"GSK, Pfizer RSV shots to get warning of rare neurological disorder"
The U.S. FDA is ordering that respiratory syncytial virus (RSV) vaccines marketed by GSK (NYSE:GSK) and Pfizer (NYSE:PFE) contain a warning on labeling of the risk of developing the rare neurological disorder Guillain-Barré syndrome ("GBS").
The FDA Safety Communication impacts GSK's Arexvy and Pfizer's Abrysvo.
The agency said it made the decision based on post-marketing observational studies of the two shots, as well as adverse event reports.
Analyses of all GBS cases based on claims data suggest an increased risk of the disease during the 42 days following vaccination, with an estimated nine excess cases of GBS per million doses of Abrysvo, and seven excess cases per million doses of Arexvy, according to the FDA.
With GBS, an individual's immune system wrongly attacks part of their peripheral nervous system, which carries signals from the brain and spinal cord to the rest of the body. |
15p/share dividend pays out tomorrow ..... ;0) |
Well at this embarrassingly low share price I've sold a few other holdings and added to my GSK today. |
More good news for GSK
"GSK ADC gets FDA breakthrough therapy designation"
GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
And yet sentiment in stock seems unmovable.
Tempted to buy myself. |
Good time to short GSK? I'm thinking so. |
Mega volume today post 2.30pm let's hope a US bidder is moving in |
I suppose you can't compare GSK to Nvidia though or any of the Mag-7 stocks that drove most of the US gains. Take a company like Disney - also flat over 10 years or so.
But the innovative companies do mostly seem to originate over there, have better access to funding etc. |
Monty that's why I prefer BHP over RIOBHP delisted in London and moved to Australia, so now I can buy BHP with no stamp duty. Hopefully GSK will move to the US |
Problem I have with FTSE 100, stamp duty is a rip off, valuations are dire on the ftse. GSK shareprice below what it was 35 years ago, ok dividends.Nvidia up 170% in 2024, predicted another 50% this year. No wonder companies want to leave London market and go to US for a better rating. UK gilts and US tech for me. |
Given the rising bulk of sales are overseas perhaps its time GSK did the unthinkable and moved it's primary listing. The City or UK pension funds clearly have no interest in companies like this. Time to give it a bloody nose.... |
GSK's Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
· Mepolizumab is the only anti-interleukin-5 approved in China for the treatment of adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)
· Around 30 million people in China live with CRSwNP and experience symptoms such as sleep disturbance, breathing problems and loss of smell
· This is the third indication for mepolizumab in China for an IL-5 mediated condition |
Diversification, 6-7% yield, low gearing etc - but best check out the BRWM thread ... |
BRWM has high charges though it looks.Never looked at it but did after you gents posted. Performance has not been great and charges high or am I missing something? |
Re: mining I hold approx 50% BRWM and 50% RIO (sorry for off-topic GSK). |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
